Dramatically improve
obstructive sleep apnea (OSA)
therapy adherence
cMAP™ is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs
Predict and prevent to improve adherance
Our groundbreaking AI algorithms have been designed to deliver lower, more comfortable air pressures. This leads to an improvement in comfort and adherence on conventional CPAP machines. Building on cMAP™’s proprietary technology, we are also creating the groundwork to build the next generation of battery-enabled, wearable CPAPs.
Tested in clinical studies
cMAP™ is being developed based on tens of thousands of apneas collected from in-home patient’s CPAP machines. cMAP™ has been validated in a first-in-human trial on current CPAPs in a double-blinded sleep lab study at the QEII hospital in Halifax, Canada.
In a clinical trial, cMAP™ proved to:
Clinical validation:
-
Study completed on 70,000 apneas from CPAP users
-
High accuracies reached preceding apneas
- Integration with commercial CPAPs
- Clinicaltrials.gov #NCT04873024
- 22 patient – nights
- 35% Reduction of AHI
Improved comfort leads to
improved adherence
Aligned incentives that
benefit all stakeholders
- Revenue increase for manufacturers due to greater initial acceptance and continued patient use of CPAP machines
- Every 5 years new device (device sales)
- Increase consumable resupply purchases as more patients use their CPAP machines and for more of the machine’s useful life
- Potential for Reduced COGS and greater margins because cMAP™ technology leads to smaller more compact devices without loss of efficacy.
- Increased revenue for Durable Medical Equipment suppliers (DMEs) due to increased sales of machines and consumable resupply
- Reduction in labor cost for DMEs because more comfortable use leads to less required patient support
Want to learn more?
Learn about the benefits that increased adherence can have for your company
Contact Us
